US Patent 10239888 Targeted protein degradation using a mutant E3 ubiquitin ligase
Patent 10239888 was granted and assigned to Dana-Farber Cancer Institute on March, 2019 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10239888 Targeted protein degradation using a mutant E3 ubiquitin ligase
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
